\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ eye\\ proptosis\ \(2\)\
\-\ children\\ with\\ nf1\\ should\\ be\\ monitored\\ for\\ developmental\\ progress\\ and\\ should\\ be\\ seen\\ yearly\\ for\\ neurological\\ exams\\.\\ more\\ about\\ general\\ treatment\\ for\\ nf1\\ patients\\ will\\ be\\ discussed\\ in\\ the\\ discussion\\.\\ \\ as\\ for\\ her\\ specific\\ findings\\ on\\ this\\ ct\\ study\\,\\ treatment\\ and\\ follow\\-up\\ are\\ as\\ follows\\:\ \(0\)\
\-\ plexiform\\ neurofibroma\\:\\ \\ lesions\\ usually\\ involve\\ multiple\\ nerve\\ fascicles\\ with\\ significant\\ vascularity\\.\\ thus\\,\\ surgical\\ excision\\ is\\ generally\\ difficult\\ and\\ frustrating\\,\\ with\\ excessive\\ bleeding\\ and\\ a\\ poor\\ cosmetic\\ result\\.\\ repeated\\ debulking\\ may\\ be\\ necessary\\ for\\ severe\\ symptoms\\,\\ and\\ orbital\\ evisceration\\ for\\ extensive\\ cases\\.\\ radiotherapy\\ offers\\ no\\ benefit\\.\\ however\\,\\ farnesyl\\ transferase\\ inhibitors\\,\\ which\\ inhibit\\ growth\\ of\\ these\\ tumors\\ in\\ animals\\,\\ are\\ a\\ possible\\ treatment\\ in\\ the\\ future\\ and\\ are\\ currently\\ undergoing\\ clinical\\ trials\\.\\ \\ of\\ concern\\,\\ there\\ is\\ a\\ small\\ risk\\ of\\ malignant\\ transformation\\ of\\ these\\ tumors\\.\\ they\\ may\\ occasionally\\ erode\\ into\\ the\\ anterior\\ cranial\\ fossa\\,\\ which\\ results\\ in\\ death\\.\ \(0\)\
\-\ optic\\ nerve\\ glioma\\:\\ \\ the\\ radiologist\\ of\\ this\\ case\\ recommended\\ further\\ evaluation\\ with\\ mri\\ of\\ the\\ brain\\ and\\ orbits\\.\\ if\\ the\\ mri\\ is\\ positive\\ for\\ an\\ optic\\ nerve\\ glioma\\,\\ mri\\ and\\ an\\ ophthalmic\\ exam\\ are\\ repeated\\ every\\ 3\\-6\\ months\\.\\ otherwise\\,\\ if\\ vision\\ is\\ ok\\,\\ observation\\ is\\ the\\ treatment\\.\\ if\\ the\\ tumor\\ progresses\\,\\ the\\ child\\ should\\ be\\ referred\\ to\\ neurooncology\\ for\\ evaluation\\.\\ \\ surgical\\ excision\\ is\\ offered\\ if\\ a\\ tumor\\ approaches\\ the\\ chiasm\\.\\ surgery\\ also\\ is\\ indicated\\ for\\ pain\\ or\\ disfiguring\\ proptosis\\.\\ the\\ role\\ of\\ radiotherapy\\ remains\\ controversial\\;\\ it\\ may\\ be\\ associated\\ with\\ cns\\ complications\\.\\ more\\ recently\\,\\ chemotherapy\\ has\\ shown\\ promising\\ results\\.\ \(0\)\
\-\ \\â\\€\\¢\\	a\\ soft\\ tissue\\ mass\\ noted\\ laterally\\ to\\ the\\ lateral\\ rectus\\ muscle\\ in\\ the\\ pre\\ and\\ post\\ septal\\ portions\\ of\\ the\\ right\\ orbit\\ \ \(0\)\
\-\ \\â\\€\\¢\\	asymmetry\\ of\\ the\\ csf\\-containing\\ spaces\\ in\\ the\\ middle\\ cranial\\ fossa\\,\\ larger\\ on\\ the\\ right\\ without\\ mass\\ effect\\ on\\ the\\ temporal\\ lobe\\.\ \(0\)\
\-\ \\â\\€\\¢\\	right\\ sphenoid\\ wing\\ hypoplasia\\ causing\\ deformity\\ of\\ the\\ right\\ orbit\\,\\ which\\ is\\ widened\\ and\\ flattened\\ posteriorly\\ rather\\ than\\ conical\\.\ \(0\)\
\-\ \\â\\€\\¢\\	right\\ optic\\ nerve\\ has\\ a\\ globular\\ appearance\\ near\\ the\\ orbital\\ fissure\ \(0\)\
\-\ \\â\\€\\¢\\	unenhanced\\ brain\\ parenchyma\\ demonstrates\\ no\\ abnormality\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\	globes\\ are\\ symmetrical\\ in\\ size\\ and\\ appearance\ \(0\)\
\-\ \\â\\€\\¢\\	left\\ optic\\ nerve\\ is\\ unremarkable\ \(0\)\
\-\ neurofibromatosis\\ type\\ 1\\ \\(nf1\\)\\,\\ right\\ orbital\\ plexiform\\ neurofibroma\\,\\ sphenoid\\ wing\\ hypoplasia\\,\\ possible\\ optic\\ nerve\\ glioma\\.\ \(0\)\
\-\ soft\\ tissue\\ mass\ \(178\)\
\-\ \\â\\€\\¢\\	plexiform\\ neurofibroma\\ of\\ the\\ orbit\ \(0\)\
\-\ \\â\\€\\¢\\	dermoid\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\	infectious\\ \\(lacrimal\\ gland\\,\\ orbital\\ cellulitis\\)\ \(0\)\
\-\ \\â\\€\\¢\\	other\\ sarcoma\\ \\(i\\.e\\.\\ rhabdomyosarcoma\\,\\ lipoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\	lymphoma\ \(0\)\
\-\ right\\ middle\\ fossa\\ fluid\ \(0\)\
\-\ \\â\\€\\¢\\	epidermoid\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\	arachnoid\\ cyst\ \(0\)\
\-\ sphenoid\\ wing\\ hypoplasia\ \(2\)\
\-\ \\â\\€\\¢\\	bone\\ dysplasia\\ secondary\\ to\\ plexiform\\ neurofibroma\ \(0\)\
\-\ \\â\\€\\¢\\	congenital\\ bony\\ malformation\ \(0\)\
\-\ \\â\\€\\¢\\	trauma\ \(0\)\
\-\ right\\ optic\\ nerve\\ globular\\ appearance\ \(0\)\
\-\ \\â\\€\\¢\\	optic\\ nerve\\ glioma\ \(0\)\
\-\ \\â\\€\\¢\\	suprasellar\\ germinoma\ \(0\)\
\-\ \\â\\€\\¢\\	craniopharyngioma\ \(0\)\
\-\ \\â\\€\\¢\\	infiltrative\\ disorders\\ such\\ as\\ sarcoidosis\\,\\ lymphoma\\,\\ and\\ langerhans\\ histiocytosis\\.\ \(0\)\
\-\ 21\\ month\\ old\\ girl\\ with\\ proptosis\ \(1\)\
\-\ our\\ patient\\ has\\ been\\ given\\ the\\ definitive\\ diagnosis\\ of\\ nf1\\ because\\ of\\ the\\ plexiform\\ neurofibroma\\ and\\ sphenoid\\ hypoplasia\\.\\ \\ it\\ is\\ a\\ likely\\ assumption\\ that\\ the\\ optic\\ nerve\\ mass\\ is\\ an\\ optic\\ nerve\\ glioma\\ given\\ this\\ patient\\â\\€\\™s\\ diagnosis\\ of\\ nf1\\.\\ \\ follow\\-up\\ mri\\ should\\ reveal\\ a\\ hypotense\\ to\\ isotense\\ t1\\ signal\\ and\\ variable\\ intensity\\ compared\\ to\\ muscle\\ on\\ t2\\ weighted\\ imaging\\.\\ \\ enhancement\\ with\\ gadolinium\\ is\\ also\\ variable\\.\\ typically\\,\\ the\\ lesion\\ appears\\ as\\ a\\ fusiform\\ enlargement\\ of\\ the\\ optic\\ nerve\\,\\ possibly\\ involving\\ the\\ optic\\ chiasm\\.\\ the\\ nerve\\ may\\ appear\\ kinked\\ with\\ cystic\\ spaces\\.\ \(0\)\
\-\ if\\ no\\ potential\\ problem\\ develops\\,\\ this\\ 2\\ year\\ old\\ needs\\ yearly\\ medical\\ visits\\ to\\ include\\ physical\\ exam\\,\\ ophthalmologic\\ exam\\,\\ growth\\ measurements\\,\\ assessment\\ for\\ precocious\\ puberty\\,\\ developmental\\ assessment\\,\\ and\\ review\\ of\\ educational\\ progress\\.\\ also\\,\\ as\\ previously\\ mentioned\\,\\ because\\ of\\ her\\ tumors\\,\\ she\\ would\\ need\\ a\\ follow\\-up\\ mri\\ every\\ 3\\-6\\ months\\.\\ \\ obviously\\,\\ this\\ management\\ involves\\ a\\ multidisciplinary\\ team\\ involving\\ genetics\\,\\ neurology\\,\\ ophthalmology\\,\\ dermatology\\,\\ neurosurgery\\,\\ and\\ plastic\\ surgery\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.33237921498851847\ \(0\)\
\-\ nerve\\:\\ 0\\.30049927110072994\ \(0\)\
\-\ plexiform\\:\\ 0\\.2311602325471802\ \(0\)\
\-\ nf1\\:\\ 0\\.2130753897363992\ \(0\)\
\-\ the\\:\\ 0\\.19611554906122122\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.1735691877626238\ \(0\)\
\-\ glioma\\:\\ 0\\.14909575960690258\ \(0\)\
\-\ sphenoid\\:\\ 0\\.14123922719658472\ \(0\)\
\-\ hypoplasia\\:\\ 0\\.13847955422820243\ \(0\)\
\-\ orbital\\:\\ 0\\.12315651153305271\ \(0\)\
\-\ of\\:\\ 0\\.11677829994577538\ \(0\)\
\-\ and\\:\\ 0\\.116054473576983\ \(0\)\
\-\ is\\:\\ 0\\.11535515042780888\ \(0\)\
\-\ wing\\:\\ 0\\.11454350579188316\ \(0\)\
\-\ for\\:\\ 0\\.10639155678543696\ \(0\)\
\-\ proptosis\\:\\ 0\\.10624499421906695\ \(0\)\
\-\ right\\:\\ 0\\.10473997574544254\ \(0\)\
\-\ if\\:\\ 0\\.10197575656646538\ \(0\)\
\-\ orbit\\:\\ 0\\.09752869327529734\ \(0\)\
\-\ globular\\:\\ 0\\.09376077324515923\ \(0\)\
\-\ should\\:\\ 0\\.09161628758701605\ \(0\)\
\-\ mri\\:\\ 0\\.09009133613370311\ \(0\)\
\-\ be\\:\\ 0\\.0854369398618987\ \(0\)\
\-\ yearly\\:\\ 0\\.08276048572280276\ \(0\)\
\-\ fossa\\:\\ 0\\.08266902869361302\ \(0\)\
\-\ tumors\\:\\ 0\\.07744720656571452\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.07603412896169172\ \(0\)\
\-\ chiasm\\:\\ 0\\.0745128021971538\ \(0\)\
\-\ repeated\\:\\ 0\\.07290524924777103\ \(0\)\
\-\ progress\\:\\ 0\\.07148362298031162\ \(0\)\
\-\ may\\:\\ 0\\.07065779189865241\ \(0\)\
\-\ as\\:\\ 0\\.07050865473462017\ \(0\)\
\-\ assessment\\:\\ 0\\.06869270574500878\ \(0\)\
\-\ variable\\:\\ 0\\.06816892119336058\ \(0\)\
\-\ every\\:\\ 0\\.06799916568341324\ \(0\)\
\-\ treatment\\:\\ 0\\.06688383648110412\ \(0\)\
\-\ are\\:\\ 0\\.06659811840864138\ \(0\)\
\-\ spaces\\:\\ 0\\.06388228306976015\ \(0\)\
\-\ appearance\\:\\ 0\\.06348495890680558\ \(0\)\
\-\ in\\:\\ 0\\.06112571976060811\ \(0\)\
\-\ cyst\\:\\ 0\\.06074719907871032\ \(0\)\
\-\ developmental\\:\\ 0\\.06070915976350166\ \(0\)\
\-\ this\\:\\ 0\\.060308446985406154\ \(0\)\
\-\ growth\\:\\ 0\\.05788855112815841\ \(0\)\
\-\ cranial\\:\\ 0\\.0573802219086273\ \(0\)\
\-\ frustrating\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ farnesyl\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ transferase\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ neurooncology\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ disfiguring\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ hypotense\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ isotense\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ educational\\:\\ 0\\.05613578655598138\ \(0\)\
\-\ excision\\:\\ 0\\.0553516657191606\ \(0\)\
\-\ with\\:\\ 0\\.05498732938925471\ \(0\)\
\-\ results\\:\\ 0\\.054705322104063106\ \(0\)\
\-\ animals\\:\\ 0\\.053640740926930386\ \(0\)\
\-\ mass\\:\\ 0\\.05363215251630289\ \(0\)\
\-\ exam\\:\\ 0\\.05301113729309806\ \(0\)\
\-\ to\\:\\ 0\\.052652630217403955\ \(0\)\
\-\ evisceration\\:\\ 0\\.05187047788068161\ \(0\)\
\-\ inhibit\\:\\ 0\\.05187047788068161\ \(0\)\
\-\ promising\\:\\ 0\\.05187047788068161\ \(0\)\
\-\ assumption\\:\\ 0\\.05187047788068161\ \(0\)\
\-\ kinked\\:\\ 0\\.05187047788068161\ \(0\)\
\-\ fascicles\\:\\ 0\\.05049735518473582\ \(0\)\
\-\ erode\\:\\ 0\\.05049735518473582\ \(0\)\
\-\ ok\\:\\ 0\\.05049735518473582\ \(0\)\
\-\ middle\\:\\ 0\\.05020174001520954\ \(0\)\
\-\ muscle\\:\\ 0\\.049849526107484186\ \(0\)\
\-\ also\\:\\ 0\\.04953296572338384\ \(0\)\
\-\ conical\\:\\ 0\\.049375432251630616\ \(0\)\
\-\ involving\\:\\ 0\\.049173968030085224\ \(0\)\
\-\ because\\:\\ 0\\.04906489423477146\ \(0\)\
\-\ offers\\:\\ 0\\.04842685992758334\ \(0\)\
\-\ multidisciplinary\\:\\ 0\\.04842685992758334\ \(0\)\
\-\ given\\:\\ 0\\.04829325766078811\ \(0\)\
\-\ has\\:\\ 0\\.04810075256604951\ \(0\)\
\-\ which\\:\\ 0\\.04788372588992287\ \(0\)\
\-\ possible\\:\\ 0\\.04756716039966393\ \(0\)\
\-\ ophthalmologic\\:\\ 0\\.046880386622579616\ \(0\)\
\-\ obviously\\:\\ 0\\.046880386622579616\ \(0\)\
\-\ globes\\:\\ 0\\.04623204650943604\ \(0\)\
\-\ precocious\\:\\ 0\\.04623204650943604\ \(0\)\
\-\ approaches\\:\\ 0\\.045645551536701155\ \(0\)\
\-\ inhibitors\\:\\ 0\\.044617577599070105\ \(0\)\
\-\ her\\:\\ 0\\.04385951329992576\ \(0\)\
\-\ brain\\:\\ 0\\.04376502470260502\ \(0\)\
\-\ cosmetic\\:\\ 0\\.04373700088038504\ \(0\)\
\-\ trials\\:\\ 0\\.04373700088038504\ \(0\)\
\-\ visits\\:\\ 0\\.04333986053008206\ \(0\)\
\-\ puberty\\:\\ 0\\.04333986053008206\ \(0\)\
\-\ genetics\\:\\ 0\\.04333986053008206\ \(0\)\
\-\ debulking\\:\\ 0\\.042966804514530624\ \(0\)\
\-\ flattened\\:\\ 0\\.042966804514530624\ \(0\)\
\-\ evaluation\\:\\ 0\\.042814373378498596\ \(0\)\
\-\ on\\:\\ 0\\.04240566143941272\ \(0\)\
\-\ germinoma\\:\\ 0\\.042282373156145636\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04181086391522444\ \(0\)\
\-\ ophthalmic\\:\\ 0\\.04166650562323256\ \(0\)\
\-\ offered\\:\\ 0\\.04166650562323256\ \(0\)\
\-\ lacrimal\\:\\ 0\\.04166650562323256\ \(0\)\
\-\ plastic\\:\\ 0\\.04166650562323256\ \(0\)\
\-\ ophthalmology\\:\\ 0\\.04138024286140138\ \(0\)\
\-\ progresses\\:\\ 0\\.04110670717685517\ \(0\)\
\-\ months\\:\\ 0\\.040864441883007974\ \(0\)\
\-\ measurements\\:\\ 0\\.04084481490103106\ \(0\)\
\-\ an\\:\\ 0\\.0402686945079527\ \(0\)\
\-\ controversial\\:\\ 0\\.040120032318228846\ \(0\)\
\-\ orbits\\:\\ 0\\.03968030674832209\ \(0\)\
\-\ symmetrical\\:\\ 0\\.03968030674832209\ \(0\)\
\-\ these\\:\\ 0\\.03964422076365272\ \(0\)\
\-\ needs\\:\\ 0\\.03926991872944989\ \(0\)\
\-\ more\\:\\ 0\\.03854953699549316\ \(0\)\
\-\ unenhanced\\:\\ 0\\.03834976927198007\ \(0\)\
\-\ excessive\\:\\ 0\\.037857223294719335\ \(0\)\
\-\ fusiform\\:\\ 0\\.037857223294719335\ \(0\)\
\-\ develops\\:\\ 0\\.037857223294719335\ \(0\)\
\-\ surgery\\:\\ 0\\.03774467121484756\ \(0\)\
\-\ monitored\\:\\ 0\\.037701429158836494\ \(0\)\
\-\ team\\:\\ 0\\.037549482187613954\ \(0\)\
\-\ soft\\:\\ 0\\.03737514684758177\ \(0\)\
\-\ benefit\\:\\ 0\\.0372564010985769\ \(0\)\
\-\ asymmetry\\:\\ 0\\.0372564010985769\ \(0\)\
\-\ widened\\:\\ 0\\.0372564010985769\ \(0\)\
\-\ mentioned\\:\\ 0\\.03711493418610161\ \(0\)\
\-\ neurology\\:\\ 0\\.03711493418610161\ \(0\)\
\-\ role\\:\\ 0\\.03684139850155539\ \(0\)\
\-\ cellulitis\\:\\ 0\\.03684139850155539\ \(0\)\
\-\ langerhans\\:\\ 0\\.03684139850155539\ \(0\)\
\-\ tissue\\:\\ 0\\.03682746674450393\ \(0\)\
\-\ tumor\\:\\ 0\\.036720795833177035\ \(0\)\
\-\ diagnosis\\:\\ 0\\.03639328636986695\ \(0\)\
\-\ rectus\\:\\ 0\\.036328306462890696\ \(0\)\
\-\ radiologist\\:\\ 0\\.03620645021017985\ \(0\)\
\-\ infiltrative\\:\\ 0\\.035969746425005715\ \(0\)\
\-\ it\\:\\ 0\\.03593647634667006\ \(0\)\
\-\ transformation\\:\\ 0\\.03585472364292907\ \(0\)\
\-\ exams\\:\\ 0\\.035630933901684016\ \(0\)\
\-\ laterally\\:\\ 0\\.035522018851794866\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.035522018851794866\ \(0\)\
\-\ neurosurgery\\:\\ 0\\.035522018851794866\ \(0\)\
\-\ future\\:\\ 0\\.035206383529785494\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.035206383529785494\ \(0\)\
\-\ vascularity\\:\\ 0\\.035104669814449894\ \(0\)\
\-\ discussed\\:\\ 0\\.03480924317948251\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.03480924317948251\ \(0\)\
\-\ problem\\:\\ 0\\.03461988855705061\ \(0\)\
\-\ death\\:\\ 0\\.03443618716393107\ \(0\)\
\-\ suprasellar\\:\\ 0\\.03443618716393107\ \(0\)\
\-\ follows\\:\\ 0\\.03434635287250439\ \(0\)\
\-\ dermatology\\:\\ 0\\.03434635287250439\ \(0\)\
\-\ fissure\\:\\ 0\\.03425781120573822\ \(0\)\
\-\ no\\:\\ 0\\.034244341518310094\ \(0\)\
\-\ septal\\:\\ 0\\.034170525491558044\ \(0\)\
\-\ surgical\\:\\ 0\\.03412146251984613\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.03391585992199462\ \(0\)\
\-\ occasionally\\:\\ 0\\.03367131623300333\ \(0\)\
\-\ remains\\:\\ 0\\.03343612048353672\ \(0\)\
\-\ portions\\:\\ 0\\.03335967801387807\ \(0\)\
\-\ possibly\\:\\ 0\\.03299109242327712\ \(0\)\
\-\ observation\\:\\ 0\\.03291995244397133\ \(0\)\
\-\ cns\\:\\ 0\\.03278009324925141\ \(0\)\
\-\ need\\:\\ 0\\.032314197550431516\ \(0\)\
\-\ thus\\:\\ 0\\.03225042972927802\ \(0\)\
\-\ concern\\:\\ 0\\.032187315948585746\ \(0\)\
\-\ arachnoid\\:\\ 0\\.03206299778759092\ \(0\)\
\-\ definitive\\:\\ 0\\.03206299778759092\ \(0\)\
\-\ undergoing\\:\\ 0\\.03188110652529006\ \(0\)\
\-\ larger\\:\\ 0\\.03142081429294362\ \(0\)\
\-\ potential\\:\\ 0\\.03136562522638424\ \(0\)\
\-\ rather\\:\\ 0\\.03109686899036856\ \(0\)\
\-\ our\\:\\ 0\\.03109686899036856\ \(0\)\
\-\ disorders\\:\\ 0\\.0309925692108328\ \(0\)\
\-\ posteriorly\\:\\ 0\\.030941074854485717\ \(0\)\
\-\ involve\\:\\ 0\\.03089000784212115\ \(0\)\
\-\ discussion\\:\\ 0\\.030739301378850337\ \(0\)\
\-\ recently\\:\\ 0\\.030640842643582022\ \(0\)\
\-\ involves\\:\\ 0\\.030543934504182742\ \(0\)\
\-\ epidermoid\\:\\ 0\\.030496046794226128\ \(0\)\
\-\ lipoma\\:\\ 0\\.03044852887722499\ \(0\)\
\-\ vision\\:\\ 0\\.030401375085770493\ \(0\)\
\-\ generally\\:\\ 0\\.029734274166406845\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.029734274166406845\ \(0\)\
\-\ dermoid\\:\\ 0\\.029650551246694842\ \(0\)\
\-\ poor\\:\\ 0\\.029609113112502864\ \(0\)\
\-\ reveal\\:\\ 0\\.0295270647013069\ \(0\)\
\-\ sarcoma\\:\\ 0\\.029446095905829073\ \(0\)\
\-\ necessary\\:\\ 0\\.02936617868290454\ \(0\)\
\-\ gadolinium\\:\\ 0\\.029248215843593887\ \(0\)\
\-\ difficult\\:\\ 0\\.029132471873157338\ \(0\)\
\-\ child\\:\\ 0\\.02905650128261965\ \(0\)\
\-\ review\\:\\ 0\\.028907317256743403\ \(0\)\
\-\ indicated\\:\\ 0\\.02887057959733324\ \(0\)\
\-\ neurological\\:\\ 0\\.028834059966859057\ \(0\)\
\-\ causing\\:\\ 0\\.028834059966859057\ \(0\)\
\-\ children\\:\\ 0\\.02876166454744409\ \(0\)\
\-\ bleeding\\:\\ 0\\.02869011095431365\ \(0\)\
\-\ pre\\:\\ 0\\.02869011095431365\ \(0\)\
\-\ deformity\\:\\ 0\\.02869011095431365\ \(0\)\
\-\ near\\:\\ 0\\.028584316835502055\ \(0\)\
\-\ parenchyma\\:\\ 0\\.028514784573951634\ \(0\)\
\-\ gland\\:\\ 0\\.028514784573951634\ \(0\)\
\-\ compared\\:\\ 0\\.028378033620072508\ \(0\)\
\-\ infectious\\:\\ 0\\.02824425574979934\ \(0\)\
\-\ general\\:\\ 0\\.028178441863897574\ \(0\)\
\-\ previously\\:\\ 0\\.028178441863897574\ \(0\)\
\-\ eye\\:\\ 0\\.028081022314593675\ \(0\)\
\-\ 21\\:\\ 0\\.028048888875131735\ \(0\)\
\-\ recommended\\:\\ 0\\.02792200727328597\ \(0\)\
\-\ appear\\:\\ 0\\.027645742141068606\ \(0\)\
\-\ shown\\:\\ 0\\.02721119413955626\ \(0\)\
\-\ malformation\\:\\ 0\\.027072906529488926\ \(0\)\
\-\ extensive\\:\\ 0\\.02704561806049487\ \(0\)\
\-\ bony\\:\\ 0\\.02704561806049487\ \(0\)\
\-\ currently\\:\\ 0\\.02696447130646841\ \(0\)\
\-\ temporal\\:\\ 0\\.02696447130646841\ \(0\)\
\-\ enlargement\\:\\ 0\\.026910961928652558\ \(0\)\
\-\ complications\\:\\ 0\\.026884380722422774\ \(0\)\
\-\ dysplasia\\:\\ 0\\.026884380722422774\ \(0\)\
\-\ specific\\:\\ 0\\.0265993237095273\ \(0\)\
\-\ about\\:\\ 0\\.026278625828882966\ \(0\)\
\-\ result\\:\\ 0\\.026278625828882966\ \(0\)\
\-\ weighted\\:\\ 0\\.026183220201925216\ \(0\)\
\-\ referred\\:\\ 0\\.02597381679391278\ \(0\)\
\-\ management\\:\\ 0\\.02592823481012873\ \(0\)\
\-\ appears\\:\\ 0\\.02570525607905602\ \(0\)\
\-\ abnormality\\:\\ 0\\.025532513797780078\ \(0\)\
\-\ congenital\\:\\ 0\\.02522113845494654\ \(0\)\
\-\ risk\\:\\ 0\\.025081051827274308\ \(0\)\
\-\ they\\:\\ 0\\.025081051827274308\ \(0\)\
\-\ malignant\\:\\ 0\\.02502197739271219\ \(0\)\
\-\ otherwise\\:\\ 0\\.02502197739271219\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.024924763053742093\ \(0\)\
\-\ intensity\\:\\ 0\\.024924763053742093\ \(0\)\
\-\ would\\:\\ 0\\.0248480824393951\ \(0\)\
\-\ typically\\:\\ 0\\.024642008581443626\ \(0\)\
\-\ effect\\:\\ 0\\.02462361233553409\ \(0\)\
\-\ girl\\:\\ 0\\.02462361233553409\ \(0\)\
\-\ size\\:\\ 0\\.023767576186457987\ \(0\)\
\-\ cases\\:\\ 0\\.023609784472348315\ \(0\)\
\-\ type\\:\\ 0\\.023547783548097043\ \(0\)\
\-\ unremarkable\\:\\ 0\\.023532380436991372\ \(0\)\
\-\ study\\:\\ 0\\.023410524184280527\ \(0\)\
\-\ positive\\:\\ 0\\.02313043451075207\ \(0\)\
\-\ further\\:\\ 0\\.02286254053770617\ \(0\)\
\-\ patient\\:\\ 0\\.022833855927395116\ \(0\)\
\-\ will\\:\\ 0\\.022592605169015196\ \(0\)\
\-\ such\\:\\ 0\\.02257941429649629\ \(0\)\
\-\ medical\\:\\ 0\\.02230874378855057\ \(0\)\
\-\ clinical\\:\\ 0\\.02224601603157156\ \(0\)\
\-\ severe\\:\\ 0\\.022221102881454263\ \(0\)\
\-\ usually\\:\\ 0\\.02209802798537401\ \(0\)\
\-\ t1\\:\\ 0\\.021870757735170946\ \(0\)\
\-\ month\\:\\ 0\\.021352970129949744\ \(0\)\
\-\ cystic\\:\\ 0\\.021140758077301057\ \(0\)\
\-\ likely\\:\\ 0\\.02097610505226881\ \(0\)\
\-\ she\\:\\ 0\\.02089540173587441\ \(0\)\
\-\ include\\:\\ 0\\.02088538783671783\ \(0\)\
\-\ secondary\\:\\ 0\\.020805857945553587\ \(0\)\
\-\ old\\:\\ 0\\.020777577620823252\ \(0\)\
\-\ however\\:\\ 0\\.020776297249761055\ \(0\)\
\-\ been\\:\\ 0\\.020450839835205487\ \(0\)\
\-\ trauma\\:\\ 0\\.0203859186938961\ \(0\)\
\-\ lobe\\:\\ 0\\.020285263756144097\ \(0\)\
\-\ significant\\:\\ 0\\.02026713844208595\ \(0\)\
\-\ fluid\\:\\ 0\\.02026713844208595\ \(0\)\
\-\ enhancement\\:\\ 0\\.020204117002117637\ \(0\)\
\-\ t2\\:\\ 0\\.0201951663973778\ \(0\)\
\-\ lesions\\:\\ 0\\.0201594936037141\ \(0\)\
\-\ than\\:\\ 0\\.019898342405710336\ \(0\)\
\-\ signal\\:\\ 0\\.019898342405710336\ \(0\)\
\-\ patients\\:\\ 0\\.019746811200149497\ \(0\)\
\-\ anterior\\:\\ 0\\.01959892195388356\ \(0\)\
\-\ symptoms\\:\\ 0\\.01920584200602003\ \(0\)\
\-\ bone\\:\\ 0\\.0191527612360743\ \(0\)\
\-\ post\\:\\ 0\\.01910013443062295\ \(0\)\
\-\ physical\\:\\ 0\\.0190331260769352\ \(0\)\
\-\ into\\:\\ 0\\.018659634489649465\ \(0\)\
\-\ noted\\:\\ 0\\.01861104452740629\ \(0\)\
\-\ without\\:\\ 0\\.01851500070989532\ \(0\)\
\-\ associated\\:\\ 0\\.01850140172165635\ \(0\)\
\-\ imaging\\:\\ 0\\.018447304321166546\ \(0\)\
\-\ other\\:\\ 0\\.018229047365521084\ \(0\)\
\-\ small\\:\\ 0\\.018106808893506795\ \(0\)\
\-\ case\\:\\ 0\\.017634877808805044\ \(0\)\
\-\ demonstrates\\:\\ 0\\.017634877808805044\ \(0\)\
\-\ lateral\\:\\ 0\\.017420366245784174\ \(0\)\
\-\ findings\\:\\ 0\\.01732425940069864\ \(0\)\
\-\ multiple\\:\\ 0\\.01716916648294358\ \(0\)\
\-\ lesion\\:\\ 0\\.016828693704654885\ \(0\)\
\-\ seen\\:\\ 0\\.01652575117172251\ \(0\)\
\-\ that\\:\\ 0\\.01523296432765344\ \(0\)\
\-\ there\\:\\ 0\\.013966988513203478\ \(0\)\
\-\ ct\\:\\ 0\\.013363672113721223\ \(0\)\
\-\ pain\\:\\ 0\\.012560797877888066\ \(0\)\
\-\ or\\:\\ 0\\.012211370947109591\ \(0\)\
\-\ left\\:\\ 0\\.011974067763493064\ \(0\)\
\-\ year\\:\\ 0\\.010817754324815092\ \(0\)\
